Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
Chondrocalcinosis, recently renamed the calcium pyrophosphate deposition (CPPD) disease, is a
very frequent affection of the elderly and causes very painful arthritis.
International recommendations for the treatment of patients suffering from CPPD are based
upon rare studies, not randomized, with small samples, and thus very weak scientific
evidence.
The treatment of CPPD arthritis is extrapolated from the experience of gout treatment,
another crystal deposition disease.
Among recommended treatments, colchicine and oral steroids are recommended as first-line
treatments, while NSAIDs are used with caution in elderly populations of patients.
Colchicine utilization is not risk-free, in particular with old patients and patients with
renal impairment.
Drug interactions of colchicine can have serious consequences, especially in a polymedicated
old patient's population.
Oral steroids are an interesting alternative in this indication with a potential of being
better tolerated, but comparative efficacy with colchicine needs to be studied.
From a broader point of view, colchicine and oral steroids have never been compared in any
crystal related arthritis.
This is the first large randomized controlled trial for CPPD acute arthritis.
Phase:
Phase 3
Details
Lead Sponsor:
Lille Catholic University
Collaborators:
Armentières Hospital Centre Bichat Hospital Centre Hospitalier Universitaire, Amiens Dunkerque Hospital Centre Hopital Lariboisière University Hospital, Caen University Hospital, Lille Valenciennes Hospital Centre